Advances in Immunotherapy for Malignant Pleural Mesothelioma.
10.3779/j.issn.1009-3419.2022.101.17
- Author:
Yujia CHI
1
;
Yiliang LIU
1
;
Jun ZHAO
1
Author Information
1. Department of Thoracic Medical Oncology, Peking University School of Oncology, Beijing Cancer Hospital & Institute,
Beijing 100042, China.
- Publication Type:Journal Article
- Keywords:
Biomarkers;
Combination therapy;
Immune checkpoint inhibitors;
Immunotherapy;
Malignant pleural mesothelioma
- MeSH:
Combined Modality Therapy;
Humans;
Immunotherapy;
Lung Neoplasms/drug therapy*;
Mesothelioma/drug therapy*;
Mesothelioma, Malignant;
Pleural Neoplasms/drug therapy*
- From:
Chinese Journal of Lung Cancer
2022;25(4):259-265
- CountryChina
- Language:Chinese
-
Abstract:
Patients with malignant pleural mesothelioma (MPM) usually present with poor prognosis and short survival period, and there has been a lack of effective treatment options for a long time. Chemotherapy has limited improvement in the clinical outcome of advanced patients (the median survival is less than one year), and it is difficult to find suitable targets for targeted therapy. Recent in-depth research on immunotherapy has changed the treatment pattern of MPM. Especially, the dual immunotherapy regimen significantly improved the survival outcome of patients across subgroups and prolonged the survival time of MPM patients. Therefore, it has been approved for unresectable MPM as first-line treatment for patients. The exploration of other mono or combo immunotherapy regimens in the first and second-line settings of MPM is also underway. How to identify the best beneficial population of each regimen through predictive biomarkers is also a hot spot for researchers. This article will focus on the most up-to-date progress of MPM epidemiology, histological characteristics, pathogenesis, treatment patterns and the advances of immunotherapy in the disease.
.
